dry powder inhalation
Recently Published Documents


TOTAL DOCUMENTS

244
(FIVE YEARS 58)

H-INDEX

34
(FIVE YEARS 5)

Author(s):  
Khaled Almansour ◽  
Iman M. Alfagih ◽  
Ahmed O. Shalash ◽  
Katrina Brockbank ◽  
Raisuddin Ali ◽  
...  

Author(s):  
Daan Zillen ◽  
Max Beugeling ◽  
Wouter L.J. Hinrichs ◽  
Henderik W. Frijlink ◽  
Floris Grasmeijer

Pharmaceutics ◽  
2021 ◽  
Vol 13 (5) ◽  
pp. 632
Author(s):  
Kahori Miyamoto ◽  
Misato Yanagisawa ◽  
Hiroaki Taga ◽  
Hiromichi Yamaji ◽  
Tomomi Akita ◽  
...  

It has been previously reported that active vitamin D3 (VD3) is a candidate drug that can repair alveolar damage in chronic obstructive pulmonary disease at a very low dose. We herein report the optimization of a very low-dose formulation of VD3 for dry powder inhalation by a simple method based on time-of-flight (TOF) theory. As the preparation content of VD3 is very low, aerodynamic particle size distribution cannot be measured by pharmacopeial methods that require quantification of the main drug. Thus, a simple method based on TOF theory, which can measure aerodynamic particle size distribution without quantification, was used. The optimized formulation for an inhalation system using a lyophilized cake contained phenylalanine as the excipient (VD3 1 μg/vial + phenylalanine 0.3 mg/vial) and showed high performance with fine particle fraction ≤ 3 μm = 47.2 ± 4.4%. The difference between the results of pharmacopeial methods and simple method was examined using the formulation containing 10 µg/vial of VD3 and was within 5.0%. The preparation is expected to efficiently deliver VD3 to the lungs. Our simple method can optimize dry powder inhalation formulations more easily and rapidly even when the content of the main drug in a preparation is very low.


Pharmaceutics ◽  
2021 ◽  
Vol 13 (4) ◽  
pp. 580
Author(s):  
Nicholas Bungert ◽  
Mirjam Kobler ◽  
Regina Scherließ

High-shear mixer coatings as well as mechanofusion processes are used in the particle-engineering of dry powder inhalation carrier systems. The aim of coating the carrier particle is usually to decrease carrier–drug adhesion. This study comprises the in-depth comparison of two established dry particle coating options. Both processes were conducted with and without a model additive (magnesium stearate). In doing so, changes in the behaviour of the processed particles can be traced back to either the process or the additive. It can be stated that the coarse model carrier showed no significant changes when processed without additives. By coating the particles with magnesium stearate, the surface energy decreased significantly. This leads to a significant enhancement of the aerodynamic performance of the respective carrier-based blends. Comparing the engineered carriers with each other, the high-shear mixer coating shows significant benefits, namely, lower drug–carrier adhesion and the higher efficiency of the coating process.


Pharmaceutics ◽  
2021 ◽  
Vol 13 (2) ◽  
pp. 233
Author(s):  
Kahori Miyamoto ◽  
Yuko Ishibashi ◽  
Tomomi Akita ◽  
Chikamasa Yamashita

Ghrelin is the peptide that increases the hunger sensation and food intake and is expected to be clinically applied for treatment of diseases such as cachexia and anorexia nervosa. In the clinical application of ghrelin, injections are problematic in that they are invasive and inconvenient. Thus, we aimed to develop a formulation that can eliminate the need for injections and can be applied clinically. We prepared formulations of an hGhrelin derivative, in which the octanoyl group essential for expression of activity is modified to avoid rapid des-acylation, using lyophilizate for a dry powder inhalation (LDPI) system. The formulation of hGhrelin derivative was optimized by the addition of phenylalanine, of which the fine particle fraction of 5 µm or less was 41.7 ± 3.8%. We also performed pharmacokinetic/pharmacodynamic tests in monkeys using the optimum formulation that can be applied clinically. The absolute bioavailability of inhaled hGhrelin derivative with respect to that intravenously injected was 16.9 ± 2.6%. An increase in growth hormone was shown as an effect of the inhaled hGhrelin derivative similar to intravenous injection. The LDPI formulation can deliver the hGhrelin derivative systemically, and it is expected to be applied clinically as a substitute for injections.


2021 ◽  
Vol 1 (1) ◽  
pp. 34-44
Author(s):  
Muhammad Taher ◽  
Siti Syazwani Shaari ◽  
Deny Susanti

Introduction: The oral medication of remdesivir and hydroxychloroquine face several limitations in covid-19 therapy.  Despite having the first-pass metabolism, it also has a limitation in the patient who has hospitalised with a severe covid-19 infection. It is especially for a drug that is targeting the angiotensin-converting enzyme II (ACE2) receptor where the receptors are found abundantly in the lung, kidney, heart, and gastrointestinal tract. Therefore, an alternative delivery such as nanospray inhalation would provide a great benefit to those patients. Methods: Scientific sources from Scopus, PubMed, Google Scholar, EBSCO, ScienceDirect, and Elsevier were accessed for publication of this review article regarding the nanospray inhalation for Covid-19. Results: Since the main organ infected by SARS-CoV-2 is the esophagus and lung, inhalation may be the best route to deliver the drug to the site of action. It is proposed that poly (lactic-co-glycolic) acid to be used in the formulation. Conclusion: Poly (lactic-co-glycolic) acid (PLGA) is considered a suitable polymer since it is biocompatible and noncytotoxic, it is the most widely applied in drug delivery either as carrier or excipient for the optimal formulation and distribution of the drugs. Dry powder inhalation of remdesivir and hydroxychloroquine may be an alternative way to deliver the drug against Covid-19.


Author(s):  
Fuweng Zhang ◽  
Damiano La Zara ◽  
Feilong Sun ◽  
Mike J. Quayle ◽  
Gunilla Petersson ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document